lamellarin H: a benzo-isoquinoline-coumarin
ID Source | ID |
---|---|
PubMed CID | 460908 |
MeSH ID | M0425730 |
Synonym |
---|
(3,4-dihydroxyphenyl)-tetrahydroxy-[?]one |
14-(3,4-dihydroxyphenyl)-2,3,11,12-tetrahydroxy-6a,14a-dihydro-6h-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one |
lamellarine h |
lamellarin h |
115982-22-4 |
14-(3,4-dihydroxyphenyl)-2,3,11,12-tetrahydroxy-6a,14a-dihydro-6h-chromeno(4',3':4,5)pyrrolo(2,1-a)isoquinolin-6-one |
14-(3,4-dihydroxyphenyl)-2,3,11,12-tetrahydroxy-6a,14a-dihydro-6h-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one |
DTXSID00921887 |
12-(3,4-dihydroxyphenyl)-7,8,16,17-tetrahydroxy-4-oxa-1-azapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-5,7,9,12,14,16,18,20-octaen-3-one |
Lamellarin H is a more potent inhibitor of HIV-1 integrase but lacked the specificity required to be medicinally useful.
Excerpt | Reference | Relevance |
---|---|---|
"Lamellarin H is a more potent inhibitor of HIV-1 integrase but lacked the specificity required to be medicinally useful." | ( Total synthesis and evaluation of lamellarin alpha 20-Sulfate analogues. Bushman, FD; Faulkner, DJ; Reddy, MV; Ridley, CP; Rocha, G, 2002) | 1.04 |
Excerpt | Reference | Relevance |
---|---|---|
"Lamellarin H has been shown to be active against the topoisomerase of the Molluscum contagiosum virus (MCV) and to have anti-HIV properties. " | ( Pyrrolo[2,1-alpha]isoquinoline as a skeleton for the synthesis of bioactive lamellarin H. Li, DP; Wang, AL; Yang, G; You, YC, 2006) | 2.01 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |